GAP-134 ([2S,4R]-1-[2-Aminoacetyl]4-Benzamidopyrrolidine-2-Carboxylic Acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 14, Issue 3, 2009, Pages 207-214

  Hennan, James K ^a,d   Swillo, Robert E ^a   Morgan, Gwen A ^a   Rossman, Eric I ^a   Kantrowitz, Joel ^b   Butera, John ^b   Petersen, Jorgen S ^c   Gardell, Stephen J ^a   Vlasuk, George P ^a  

^a Cardiovascular and Metabolic Disease Research   (United States)

^b Chemical Sciences Drug Safety and Metabolism   (United States)

^c PFIZER INC   (United States)

^d Zealand Pharma AS   (Denmark)

Author keywords

Arrhythmia; Gap junction; Infarct size; Ischemia; Ventricular tachycardia

Indexed keywords

1 (2 AMINOACETYL)4 BENZAMIDOPYRROLIDINE 2 CARBOXYLIC ACID; ANTIARRHYTHMIC PEPTIDE; GAP 134; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE SIZE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; INCIDENCE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPERFUSION INJURY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZAMIDES; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; INFUSIONS, INTRAVENOUS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROLINE; TACHYCARDIA, VENTRICULAR; TIME FACTORS; VENTRICULAR PREMATURE COMPLEXES;

EID: 69949171674     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248409340779     Document Type: Article

References (27)

1. Ursell PC, Gardner PI, Albala A., Fenoglio JJ Jr, Wit AL Structural and electrophysiological changes in the epicardial border zone of canine myocardial infarcts during infarct healing. Circ Res. 1985 ; 56 (3). 436-451.
2. Dillon SM, Allessie MA, Ursell PC, Wit AL Influences of anisotropic tissue structure on reentrant circuits in the epicardial border zone of subacute canine infarcts. Circ Res. 1988 ; 63 (1). 182-206.
3. De Groot JR, Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc Res. 2004 ; 62 (2). 323-334.
4. Yao JA, Hussain W., Patel P., Peters NS, Boyden PA, Wit AL Remodeling of gap junctional channel function in epicardial border zone of healing canine infarcts. Circ Res. 2003 ; 92 (4). 437-443.
5. Xing D., Kjølbye AL, Nielsen MS, et al. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol. 2003 ; 14 (5). 510-520.
6. Hennan JK, Swillo RE, Morgan GA, et al. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/ reperfusion injury in open-chest dogs. J Pharmacol Exp Ther. 2006 ; 317 (1). 236-243.
7. Laurent G., Leong-Poi H., Mangat I., et al. Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs. Circ Arrhythmia Electrophysiol. 2009 ; 2: 171-178.
8. Rossman EI, Liu K., Morgan GA, et al. Effects of the gap junction modifier, GAP-134, on conduction and atrial fibrillation/flutter inducibility and maintenance in dogs. Revised, resubmitted to J Pharmacol Exp Ther. 2009; 329 (3). 1127-1133.
9. Butera JA, Larsen BD, Hennan JK, et al. Discovery of (2S,4R)-1-(2- aminoacetyl)-4-benzamido-pyrrolidine2-carboxylic acid hydrochloride (GAP-134)13, an Orally Active Small Molecule Gap-Junction Modifier for the Treatment of Atrial Fibrillation. J. Med Chem. 2009 ; 26 ; 52 (4). 908-911.
10. Black SC, Driscoll EM, Lucchesi BR Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion. Pharmacology. 1998 ; 57 (1). 35-46.
11. Walker MJ, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res. 1988 ; 22 (7). 447-455.
12. Heymann MA, Payne BD, Hoffman JI, Rudolph AM Blood flow measurements with radionuclide-labeled particles. Prog Cardiovasc Dis. 1977 ; 20 (1). 55-79.
13. Black SC, Rodger IW Methods for studying experimental myocardial ischemic and reperfusion injury. J Pharmacol Toxicol Methods. 1996 ; 35 (4). 179-190.
14. Kléber AG, Riegger CB, Janse MJ Electrical uncoupling and increase of extracellular resistance after induction of ischemia in isolated, arterially perfused rabbit papillary muscle. Circ Res. 1987 ; 61 (2). 271-279.
15. Smith WT 4th, Fleet WF, Johnson TA, Engle CL, Cascio WE The Ib phase of ventricular arrhythmias in ischemic in situ porcine heart is related to changes in cell-to-cell electrical coupling. Experimental Cardiology Group, University of North Carolina. Circulation. 1995 ; 92 (10). 3051-3060.
16. Yao JA, Hussain W., Patel P., Peters NS, Boyden PA, Wit AL Remodeling of gap junctional channel function in epicardial border zone of healing canine infarcts. Circ Res. 2003 ; 92 (4). 437-443.
17. Cinca J., Warren M., Carre?ño A., et al. Changes in myocardial electrical impedance induced by coronary artery occlusion in pigs with and without preconditioning: correlation with local ST-segment potential and ventricular arrhythmias. Circulation. 1997 ; 96 (9). 3079-3086.
18. Papp R., Gönczi M., Kovács M., Seprényi G., Végh A. Gap junctional uncoupling plays a trigger role in the antiarrhythmic effect of ischaemic preconditioning. Cardiovasc Res. 2007 ; 74 (3). 396-405.
19. Beardslee MA, Lerner DL, Tadros PN, et al. Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circ Res. 2000 ; 87 (8). 656-662.
20. Lampe PD, Lau AF The effects of connexin phosphorylation on gap junctional communication. Int J Biochem Cell Biol. 2004 ; 36 (7). 1171-1186.
21. Axelsen LN, Stahlhut M., Mohammed S., et al. Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123). J Mol Cell Cardiol. 2006 ; 40 (6). 790-798.
22. Schulz R., Gres P., Skyschally A., et al. Ischemic preconditioning preserves connexin 43 phosphorylation during sustained ischemia in pig hearts in vivo. FASEB J. 2003 ; 17 (10). 1355-1357.
23. García-Dorado D., Rodríguez-Sinovas A., Ruiz-Meana M. Gap junction-mediated spread of cell injury and death during myocardial ischemia-reperfusion. Cardiovasc Res. 2004 ; 61 (3). 386-401.
24. Matchkov VV, Rahman A., Peng H., Nilsson H., Aalkjaer C. Junctional and nonjunctional effects of heptanol and glycyrrhetinic acid derivates in rat mesenteric small arteries. Br J Pharmacol. 2004 ; 142 (6). 961-972.
25. Li G., Whittaker P., Yao M., Kloner RA, Przyklenk K. The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts. Cardiovasc Pathol. 2002 ; 11 (3). 158-165.
26. Burmeister WE, Reynolds RD Comparison of infarct size produced by coronary artery occlusion in purebred beagle and mixed-breed dogs. Can J Physiol Pharmacol. 1983 ; 61 (7). 672-675.
27. Jugdutt BI Difference in the relation between infarct and occluded bed in pentobarbital-anesthetized and conscious dogs. Can J Physiol Pharmacol. 1986 ; 64 (3). 254-262.